Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer

作     者：Anita Lavery Richard C.Turkington 

作者机构：Patrick G Johnston Centre for Cancer ResearchQueen’s University BelfastBelfastUK 

出 版 物：《Gastroenterology Report》 (胃肠病学报道（英文）)

年 卷 期：2020年第8卷第6期

页      面：411-424,I0001页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the Wellcome Trust and the Health Research Board[Grant Number 203930/B/16/Z] the Health Service Executive National Doctors Training and Planning the Health and Social Care Research and Development Division,Northern Ireland 

主　　题：oesophageal cancer predictive biomarkers chemotherapy radiotherapy gene expression pathological response 

摘      要：Oesophageal cancer is a devastating disease with poor outcomes and is the sixth leading cause of cancer death *** the setting of resectable disease,there is clear evidence that neoadjuvant chemotherapy and chemoradiotherapy result in improved ***,only 15%-30%of patients obtain a histopathological response to neoadjuvant therapy,often at the expense of significant *** are no predictive biomarkers in routine clinical use in this setting and the ability to stratify patients for treatment could dramatically improve *** this review,we aim to outline current progress in evaluating predictive transcriptomic biomarkers for neoadjuvant therapy in oesophageal cancer and discuss the challenges facing biomarker development in this *** place these issues in the wider context of recommendations for biomarker development and *** majority of studies focus on messenger RNA(mRNA)and microRNA(miRNA)*** studies report a range of different genes involved in a wide variety of pathways and biological processes,and this is explained to a large extent by the different platforms and analysis methods *** studies are also vastly underpowered so are not suitable for identifying a candidate *** molecular subtypes of oesophageal cancer have been proposed,although little is known about how these relate to clinical *** anticipate that the accumulating wealth of genomic and transcriptomic data and clinical trial collaborations in the coming years will provide unique opportunities to stratify patients in this poor-prognosis disease and recommend that future biomarker development incorporates well-designed retrospective and prospective analyses.